

Introduction

effectively System The Immune can differentiate self from non-self to mount an immune response.



Cancer cells exploit "self" recognition by:

- Being of human origin
- Hijacking cells: produce more self-cell surface marker CD47
- cells through CD47-SIRP α interaction



Research Question: Will the known high ligand, Thrombospondin-1, affinity CD47 outcompete the CD47-SIRP α interaction and allow THP-1 macrophage to phagocytose MCF-7 breast cancer cells?



Outcompeting Cancer's "Don't Eat Me" Signal to Promote Immune Clearance Jordan Merritt, Ph.D.¹; Lisa Alvarez, M.D.²; & Sandra Joe, Ph.D.³

Results

¹Division of Research & Economic Development, ²College of Medicine, ³College of Science

Slight TNFα



Optimize COincubation time Utilize whole cell label for THP-1

The interdisciplinary and interprofessional team included a diverse set of experts (students, lab techs, clinicians, and research scientists) from multiple departments in the College of Science Medicine, with skills in biochemistry, and medicine, biology, and morphology.

٦.	Over Aller
2.	ISelf
3.	Versu Chao Volk
4.	Maliq <u>http</u> Takir J.Y., M me" Targ <u>http</u>



Conclusion

THP-1/MCF-7 co-culture

• MCF-7 cells not clearly insideoutside THP-1 macrophage increase in production

- THP-1/MCF-7 co-culture + anti-CD47
- MCF-7 cells appear to be internalized by THP-1 macrophage
- Moderate increase in TNFα
- production



- THP-1/MCF-7 co-culture + Thrombospon din-1
- MCF-7 cells not clearly insideoutside THP-1
- macrophage Large increase in $\mathsf{TNF}\alpha$ production



Improvements:

Future Studies:

- Try other known
- CD47 ligands Use activated THP-1
- cells (M1 vs M2)

Research Team

References

rview of the Immune System. (2013). National Institute of rgy and Infectious Diseases.

<u>s://www.niaid.nih.gov/research/immune-system-overview</u> vs Non-Self]. BioNinja. <u>https://ib.bioninja.com.au/higher-</u> /topic-11-animal-physiology/111-antibody-production-and/selfus-non-self.htm

io, M.P., Takimoto, C.H., Feng, D.D., McKenna, K., Gip, P., Liu, J., kmer, J., Weissman, I.L., Majeti, R. (2020). Therapeutic Targeting he Macrophage Immune Checkpoint CD47 in Myeloid ignancies. *Frontiers in Oncology*. 22(January 2020). <u>cs://doi.org/10.3389/fonc.2019.01380</u> (imoto, C.H., Chao, M.P., Gibbs, C., McCamish, M.A., Liu, J., Chen,

Majeti, R., Weissman, I.L. (2019). The Macrophage "Do not eat "Signal, CD47, is a Clinically Validated Cancer Immunotherapy get. Annals of Oncology. 30(3). 486-489. <u>ps://doi.org/10.1093/annonc/mdz006</u>